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4 scores correlated moderately with the Visual Analogical Scale
of the EQ-5D. The dimensions which measure secondary effects
of immunosupression (Side Effects of Corticosteroids-SEC and
Increased Growth of Gum and Hair-IGGH) showed low corre-
lation with SF-36 and EQ-5D although they correlated with the
episodes of acute rejection (r > 0.4). The correlations with clin-
ical variables were low, but in accordance with expectations. The
correlations of the scores at 3 and 6 months were moderate (r =
0,7). 6 patients suffered initial allograft dysfunction and these
showed worse scores than the rest. Cronbachxs Alpha, which
evaluate the reliability, were: 0.92 for the whole questionnaire;
0.86, LPC; 0.79, LCC; 0.66, CRD; 0.63, SEC; 0.74, IGGH; 0.78,
TAPD. CONCLUSIONS: The feasibility, validity and reliability
of the Spanish version of the ESRD-scl were adequate to evalu-
ate the PHS of kidney transplant bearers.
PUK26
THE IMPACT OF THE OVERACTIVE BLADDER ON QUALITY
OF LIFE (SF36) AND UTILITY (EQ5D)
Poole C1, Odeyemi IA2, McEwan P3, Currie CJ3
1Cardiff Research Consortium, Cardiff, Wales, UK; 2Allergan Ltd, High
Wycombe, UK; 3Cardiff University, Cardiff, Wales, UK
OBJECTIVES: To demonstrate the contribution of problems
associated with an overactive bladder; namely continence,
urgency and frequency, on health related quality of life and
utility. METHODS: Patients treated by an academic urology unit
in the UK were sent a self-completed survey that included the
EQ5D and SF36 and urology disease-speciﬁc questions. Poten-
tially confounding factors were controlled using multivariate
linear regression analysis. The survey was undertaken with the
Health Outcomes Data Repository (HODaR) framework, a large
representative dataset linking clinical data to routine QoL and
utility survey responses. RESULTS: In a routine survey without
reminders, 609 surveys were retuned (28% response rate). The
mean age of respondents was 65 years (SD 15.5) and 68% were
male. Sixty percent of valid responses reported some degree of
incontinence. Of these, 60% reported stress incontinence; 85%
had urinary frequency problems and 91% had urgency. Among
the generally continent: 12% reported stress incontinence; 60%
reported frequency problems and 54% reported urgency. Con-
trolling for age, gender and body mass index (BMI), incontinence
was associated with a reduction in the EQ5Dindex (-0.11; SE
0.026, p < 0.001) and SF36 scores across all domains (max:
physical role -14.51 (SE 3.92; p < 0.001)). Under similar ana-
lytic conditions in continent respondents, urgency signiﬁcantly
reduced social and mental-role functioning (-8.55; p = 0.069 &
-14.51; p = 0.080, respectively) whilst frequency reduced the
energy domain (-9.09; p < 0.05). Among the incontinent,
urgency reduced social functioning by -17.61 (p < 0.05), and the
mental domain by -11.58 (p < 0.05) whilst frequency again
reduced the energy domain by -9.07 (p < 0.05). CONCLU-
SIONS: Incontinence has a detrimental impact on quality of life
comparable with diseases and conditions traditionally regarded
as being more serious. Urinary urgency reduces social function-
ing and mental well-being, whilst increased urinary frequency
increases tiredness.
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OBJECTIVE: The I-QOL is a 22-item incontinence-speciﬁc
measure originally developed in the USA and subsequently
adapted into numerous other language versions. The British-
English language version has not yet been validated. The purpose
of this presentation is to report the psychometric performance
characteristics of the UK version of the I-QOL. METHODS: The
I-QOL was included in a cross-sectional, descriptive health out-
comes study among female care-seekers at 17 large primary care
clinics throughout the UK. A total of 2400 women between 18
and 91 years of age took the survey while waiting to be seen by
their care providers. Twenty-two percent (n = 503) of these
women reported symptoms of stress urinary incontinence; 21%
(n = 538) mixed; and 4% (n = 85) urge incontinence without
overactive bladder. Other measures included the Scale for Activ-
ity Interference and Limitation (SAIL, incontinence-speciﬁc indi-
vidualized activity limitations), the Symptom Frequency and
Bothersomeness scale (SFB-SUI), self-perceived severity, self-
reported episodes, and a variety of other demographic and
descriptive variables. Psychometric testing was conducted using
standardized procedures. Reproducibility could not be assessed
within the study design. RESULTS: Principal component analy-
ses conﬁrmed the original measurement model of three subscales
(avoidance and limiting behavior, psychosocial impacts, and
social embarrassment) and a total summary score. Internal con-
sistency values were acceptable (alpha ranged between 0.87 and
0.95) and, as hypothesized, the I-QOL had strong associations
with both the SFB-SUI (symptoms) (>0.60) and the SAIL (limi-
tations) (>0.67) scales. Quality of life scores became signiﬁcantly
worse as the patients’ perception of severity increased (p < 0.001)
and number of incontinent episodes increased (p < 0.001). CON-
CLUSION: This cross-sectional assessment of the British-English
version has shown it to have similar psychometric performance
to those previously published for the original measure, making
this I-QOL language version a valid PRO for incorporation in
community based studies of patients with varying types and
severity of urinary incontinence.
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OBJECTIVES: To investigate the impact of long-term treatment
with darifenacin, a muscarinic M3 selective receptor antagonist,
on quality of life (QoL) in patients with overactive bladder
(OAB). METHODS: Patients with OAB for ≥6 months who par-
ticipated in two 12-week, placebo-controlled, double-blind
feeder studies of darifenacin controlled release 3.75, 7.5 or 15
mg qd were enrolled into this 2-year, multicentre, open-label
extension. During the ﬁrst 2 weeks of the extension all patients
received darifenacin 7.5mg, after which titration between dar-
ifenacin 15 and 7.5mg was permitted. The King’s Health Ques-
tionnaire [KHQ] was used to assess QoL. Here, we report data
from patients who received darifenacin 7.5 or 15mg during the
feeder studies and had a gap of £3 treatment days before enter-
ing the extension. RESULTS: A total of 303 patients who had
received darifenacin 7.5 or 15mg during the feeder studies
entered the extension (22–89 years; 86.5% female) and 199
patients (65.7%) completed the study. Darifenacin 7.5/15mg
was associated with signiﬁcant improvements in eight of nine
KHQ domains (Incontinence impact, Severity measures, Role
limitations, Physical limitations, Social limitations, Emotions,
Personal relationships and Sleep/energy) from baseline to the end
of the 12-week, double-blind feeder studies (all p < 0.001 vs.
